Real-world comparative outcomes of GLP-1 RA and semaglutide prescription among individuals with type 2 diabetes

Maxwell Salvatore, Bingyu Zhang, Huilin Tang, Yiwen Lu, Dazheng Zhang, Ting Zhou, Yuan Lu, Anastassia Amaro, Marylyn D. Ritchie, Yong ChenmedRxiv 2025 · DOI

This study, recently published as a preprint, leverages real-world data from the NIH All of Us Research Program to conduct a massive "deep dive" into the health outcomes of patients prescribed GLP-1 receptor agonists (GLP-1 RAs) like semaglutide. By comparing them against other common second-line diabetes medications, the researchers identified significant new benefits for heart, kidney, and even dental health, while also flagging potential risks for depression and nutritional deficiencies.

TL;DR

Researchers used a phenome-wide association study (PheWAS) on nearly 19,000 patients to compare GLP-1 RAs against SGLT2 and DPP4 inhibitors. The study confirms known cardiovascular and renal benefits for semaglutide but also reveals a novel protective effect on dental health and a concerning association with increased risks of dysthymic disorder and vitamin D deficiency.

What Problem Does This Paper Address?

While GLP-1 RAs (like Ozempic and Wegovy) have seen a meteoric rise in prescriptions for type 2 diabetes (T2D) and weight management, most of our knowledge comes from highly controlled clinical trials. These trials often have strict inclusion criteria and focus on a narrow set of primary endpoints (like HbA1c levels or major cardiac events).

There is a significant gap in understanding the "downstream" health effects of these drugs in diverse, real-world populations across the entire spectrum of human disease. This paper seeks to move beyond specific trial endpoints to see how these medications affect over 1,000 different health conditions simultaneously.

Methods

The authors employed a Phenome-Wide Association Study (PheWAS) approach. Unlike a traditional study that looks for one specific outcome, a PheWAS scans the entire electronic health record (EHR) for associations across hundreds of "phecodes" (grouped clinical diagnoses).

Key methodological highlights include:

  • Propensity Score Matching: To ensure a fair comparison, the researchers matched patients across drug classes based on age, sex, BMI, and baseline comorbidities.
  • ITT vs. PP Analysis: They conducted both Intention-to-Treat (analyzing patients based on their initial prescription) and Per-Protocol (analyzing only those who adhered to the medication) analyses to provide a robust view of the drug's impact.
  • Restricted Mean Survival Time (RMST): Beyond just "relative risk," they used RMST to calculate the absolute time difference (in days) until a diagnosis occurred, providing a more intuitive measure of clinical impact.

Datasets

The study utilized the NIH All of Us Research Program (AOU), a nationally recruited EHR-linked biobank.

  • Cohort Size: 18,746 adults with T2D.
  • Diversity: Unlike previous large-scale studies (which often rely on predominantly white, male Veteran Affairs data), the AOU dataset is specifically designed to oversample historically underrepresented groups, providing a more generalizable look at the US population.

Key Insights and Ideas

  • Semaglutide’s "Distinct Profile": While GLP-1 RAs as a class showed benefits, semaglutide specifically demonstrated superior protection against cardiac arrhythmias and chronic kidney disease compared to both SGLT2is and DPP4is.
  • The Dental Connection: In a novel finding, GLP-1 RAs were associated with a significantly lower risk of dental conditions (like caries and hard tissue diseases) compared to DPP4is. The authors hypothesize this may be due to the systemic anti-inflammatory effects of GLP-1 RAs.
  • Mental Health Red Flag: The study found a more than two-fold increased risk of dysthymic disorder (a form of chronic depression) in the GLP-1 RA group compared to SGLT2i users. This adds a data point to the ongoing debate regarding GLP-1s and mental health.
  • Nutritional Side Effects: A significant association with vitamin D deficiency was observed, suggesting that the rapid weight loss or metabolic shifts associated with these drugs may require closer nutritional monitoring.

Key Results

  • Cardiac Health: Semaglutide was linked to a 48% reduced risk of cardiac arrhythmia and conduction disorders compared to SGLT2is (PP HR 0.52).
  • Renal Health: Semaglutide showed a 41% to 47% reduced risk of chronic kidney disease compared to the other drug classes.
  • Dental Health: GLP-1 RAs showed a 57% reduced risk of diseases of the hard tissues of teeth compared to DPP4is (PP HR 0.43).
  • Adverse Associations: GLP-1 RAs were associated with an increased risk of dysthymic disorder (ITT HR 2.30) and vitamin D deficiency (PP HR 1.49).
  • Time Delays: RMST analysis showed that semaglutide delayed the diagnosis of hyperglycemia by an average of 78.5 days over a three-year period compared to SGLT2is.

Limitations and Future Work

The authors acknowledge several limitations inherent to EHR-based research:

  1. Causality: As an observational study, it can identify associations but cannot definitively prove that the drugs caused these outcomes.
  2. Underreporting: GLP-1 use is likely underreported in EHRs, especially with the rise of telehealth prescriptions.
  3. Generalizability: The study focused strictly on T2D patients; the results may differ for the rapidly growing population using these drugs solely for weight loss.

Future Work: The researchers suggest investigating these effects in non-diabetic populations and exploring genetic predictors to move toward "precision prescribing" for GLP-1 therapies.

Summary updated

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes (T2D) and weight management, yet their broad health impacts in real-world settings remain understudied. Using data from the All of Us Research Program (n=18,746), we conducted both intention-to-treat and per-protocol phenome-wide association studies comparing diagnoses following GLP-1 RA prescription, including semaglutide-specific analyses, to those following sodium-glucose cotransporter-2 inhibitor (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP4i) prescriptions in individuals with T2D. GLP-1 RAs were associated with reduced risks of genitourinary and dental conditions relative to comparators, while semaglutide was linked to lower risks of cardiac arrhythmia, hyperglycemia, and chronic kidney disease. However, GLP-1 RAs were also associated with increased risks of dysthymic disorder and vitamin D deficiency. Time-to-event analyses revealed modest delays in diagnosis for key outcomes. These findings underscore differences in downstream associations across second-line T2D therapies and highlight semaglutide's distinct profile. Results may inform clinical decision-making and motivate further research on effectiveness, safety, and personalized prescribing.
BibTeX
@misc{salvatore2025real,
  author = {Maxwell Salvatore and Bingyu Zhang and Huilin Tang and Yiwen Lu and Dazheng Zhang and Ting Zhou and Yuan Lu and Anastassia Amaro and Marylyn D. Ritchie and Yong Chen},
  title = {{Real-world comparative outcomes of GLP-1 RA and semaglutide prescription among individuals with type 2 diabetes}},
  year = {2025},
  doi = {10.1101/2025.06.03.25328908},
  howpublished = {medRxiv},
}
Figure